爱罗咳喘宁对慢性阻塞性肺疾病大鼠白三烯B4、白细胞介素-6及肺组织病理形态的影响

Effect of Ailuo Kechuanning on LTB4,IL-6 Levels and Pathological Morphology in Rats with Chronic Obstructive Pulmonary Disease

目的:观察爱罗咳喘宁口服液对慢性阻塞性肺疾病(COPD)大鼠模型血浆及支气管肺泡灌洗液(BALF)中白三烯B4(LTB4)、白细胞介素-6(IL-6)及肺组织病理形态的影响。方法:采用脂多糖(LPS)加烟雾诱导COPD大鼠模型,大鼠随机被分为正常组、模型组、爱罗咳喘宁口服液低、中、高剂量组。正常组、模型组灌胃蒸馏水(10 mL·kg-1·d-1),爱罗咳喘宁口服液低、中、高剂量组分别灌胃混悬液(5,10,20 g·kg-1·d-1),连续7 d。酶联免疫法(ELISA)测定各组大鼠血浆和BALF中LTB4,IL-6的含量。结果:与正常组相比,模型组大鼠血浆和BALF中LTB4,IL-6水平均显著高于正常组(均P<0.05),与模型组相比,爱罗咳喘宁口服液低、中、高剂量组LTB4和IL-6含量均显著降低(均P<0.05)。结论:爱罗咳喘宁口服液治疗COPD的作用机制可能与抑制LTB4,IL-6的释放有关。

Objective： To study the effect of Ailuo Kechuanning oral liquid on leukotriene B4 （LTB4）, interleukin-6 （IL-6） levels and pathological morphology in plasma and bronchial alveolar lavage fluid （BALF） of rats with chronic obstructive pulmonary disease （COPD）. Method： Lipopolysaccharide （LPS） combined with smoke was used to establish COPD rat model; the experimental animals were randomly divided into normal control group, model group, Ailuo Kechuanning oral liquid groups （5, 10, 20 g · kg-1- d-l）, enzyme-linked immunosorbent assay （ELISA） was used to determine the change of LTB4, IL-6 levels in rat plasma and BALF in the rats of all groups before and after treatment. Result： The levels of LTB4, IL-6 in plasma and BALF of the model group were significantly higher than those in normal control group; compared with the model group, the levels of LTB4, IL-6 in plasma and BALF of the rats treated with Ailuo Kechuanning oral liquid were significantly decreased. Conclusion： The mechanism of Ailuo Kechuanning oral liquid for treatment of COPD may be related to the inhibition of LTB4, IL-6 release.